Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest.
Article activity feed
-
-
SciScore for 10.1101/2021.06.28.449914: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources To make SARS-CoV-2 full-length S pseudotyped recombinant VSV-ΔG-firefly luciferase virus, BHK-21/WI-2 cells (Kerafast) were transfected with the S-expression plasmid and subsequently infected with VSVΔG-firefly-luciferase as previously described. BHK-21/WI-2suggested: RRID:CVCL_HB78)Recombinant DNA Sentences Resources Study protocols and results are reported previously.2 Recombinant vesicular stomatitis virus (VSV)-based pseudovirus assay: Codon-optimized full-length … SciScore for 10.1101/2021.06.28.449914: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources To make SARS-CoV-2 full-length S pseudotyped recombinant VSV-ΔG-firefly luciferase virus, BHK-21/WI-2 cells (Kerafast) were transfected with the S-expression plasmid and subsequently infected with VSVΔG-firefly-luciferase as previously described. BHK-21/WI-2suggested: RRID:CVCL_HB78)Recombinant DNA Sentences Resources Study protocols and results are reported previously.2 Recombinant vesicular stomatitis virus (VSV)-based pseudovirus assay: Codon-optimized full-length spike (S) protein of the original Wuhan-Hu-1 variant with D614G mutation (D614G) or the S variants, listed in Table 1, were cloned into a pCAGGS vector. pCAGGSsuggested: RRID:Addgene_18926)Software and Algorithms Sentences Resources The percentage of neutralization was calculated based on the RLUs of the virus-only control, and subsequently analyzed using four-parameter logistic curve in Prism v. Prismsuggested: (PRISM, RRID:SCR_005375)8 (GraphPad Software, Inc.). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04283461 Active, not recruiting Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
